Stock Track | Hims & Hers Health Soars 5.11% In Pre-Market Trading On Bullish Analyst Coverage

Stock Track

Jan 07, 2025

Hims & Hers Health Inc. (HIMS) stock soared 5.11% in the pre-market trading session on Tuesday. This significant surge can be attributed to the initiation of bullish analyst coverage by BTIG.

BTIG initiated coverage on Hims & Hers Health with a "Buy" rating and a price target of $35, citing the company's disruptive approach to healthcare using technology and convenience. The analyst firm praised Hims & Hers for offering access to medications and personalized treatment plans, insulating it from the risk of patients returning to in-person visits.

Furthermore, BTIG highlighted the company's potential for robust revenue growth and increasing demand for its GLP-1 and other obesity health products, such as compounded versions of Novo Nordisk's Wegovy and Ozempic. The firm believes that the compounding trend for GLP-1s is likely to continue, boding well for Hims & Hers Health's future prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1184711161"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184711161\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184711161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 22:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184711161","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.11% In Pre-Market Trading On Bullish Analyst Coverage","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) stock soared 5.11% in the pre-market trading session on Tuesday. This significant surge can be attributed to the initiation of bullish analyst coverage by BTIG.</p>\n\n<p>BTIG initiated coverage on Hims & Hers Health with a \"Buy\" rating and a price target of $35, citing the company's disruptive approach to healthcare using technology and convenience. The analyst firm praised Hims & Hers for offering access to medications and personalized treatment plans, insulating it from the risk of patients returning to in-person visits.</p>\n\n<p>Furthermore, BTIG highlighted the company's potential for robust revenue growth and increasing demand for its GLP-1 and other obesity health products, such as compounded versions of Novo Nordisk's Wegovy and Ozempic. The firm believes that the compounding trend for GLP-1s is likely to continue, boding well for Hims & Hers Health's future prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.11% In Pre-Market Trading On Bullish Analyst Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.11% In Pre-Market Trading On Bullish Analyst Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-07 22:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) stock soared 5.11% in the pre-market trading session on Tuesday. This significant surge can be attributed to the initiation of bullish analyst coverage by BTIG.</p>\n\n<p>BTIG initiated coverage on Hims & Hers Health with a \"Buy\" rating and a price target of $35, citing the company's disruptive approach to healthcare using technology and convenience. The analyst firm praised Hims & Hers for offering access to medications and personalized treatment plans, insulating it from the risk of patients returning to in-person visits.</p>\n\n<p>Furthermore, BTIG highlighted the company's potential for robust revenue growth and increasing demand for its GLP-1 and other obesity health products, such as compounded versions of Novo Nordisk's Wegovy and Ozempic. The firm believes that the compounding trend for GLP-1s is likely to continue, boding well for Hims & Hers Health's future prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1184711161","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184711161","pubTimestamp":1736261199,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.  stock soared 5.11% in the pre-market trading session on Tuesday. This significant surge can be attributed to the initiation of bullish analyst coverage by BTIG.BTIG initiated coverage on Hims & Hers Health with a \"Buy\" rating and a price target of $35, citing the company's disruptive approach to healthcare using technology and convenience. The analyst firm praised Hims & Hers for offering access to medications and personalized treatment plans, insulating it from the risk","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"由于分析师的看涨报道，Hims&Hers Health在盘前交易中飙升5.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) stock soared 5.11% in the pre-market trading session on Tuesday. This significant surge can be attributed to the initiation of bullish analyst coverage by BTIG.\nBTIG initiated coverage on Hims & Hers Health with a \"Buy\" rating and a price target of $35, citing the company's disruptive approach to healthcare using technology and convenience. The analyst firm praised Hims & Hers for offering access to medications and personalized treatment plans, insulating it from the risk of patients returning to in-person visits.\nFurthermore, BTIG highlighted the company's potential for robust revenue growth and increasing demand for its GLP-1 and other obesity health products, such as compounded versions of Novo Nordisk's Wegovy and Ozempic. The firm believes that the compounding trend for GLP-1s is likely to continue, boding well for Hims & Hers Health's future prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}